Adaptive Biotechnologies financials
$28.77+0.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.6M | $70.9M | $71.7M | $94.0M | $58.9M | $52.4M | $47.5M | $46.4M | $43.2M | $41.9M | $45.8M | $37.9M |
| Gross profit | $51.4M | $52.2M | $53.5M | $75.8M | $40.9M | $35.5M | $29.4M | $29.8M | $23.9M | $23.8M | $26.2M | $18.6M |
| Gross margin | 71.8% | 73.6% | 74.6% | 80.7% | 69.4% | 67.6% | 62.0% | 64.1% | 55.3% | 56.9% | 57.2% | 49.0% |
| Operating income | -$15.8M | -$19.2M | -$12.8M | $10.3M | -$25.0M | -$29.6M | -$33.8M | -$32.6M | -$47.3M | -$48.8M | -$71.1M | -$51.0M |
| Net income | -$39.8M | -$20.0M | -$13.6M | $9.5M | -$25.6M | -$29.9M | -$33.7M | -$32.1M | -$46.2M | -$47.5M | -$69.4M | -$50.3M |
| Net margin | −55.6% | −28.3% | −18.9% | 10.2% | −43.5% | −56.9% | −71.0% | −69.1% | −107.0% | −113.5% | −151.7% | −132.7% |
| Diluted EPS | $-0.25 | $-0.13 | $-0.10 | $0.06 | $-0.17 | $-0.20 | $-0.23 | $-0.22 | $-0.31 | $-0.33 | $-0.48 | $-0.35 |
| EBITDA | -$12.1M | -$15.4M | -$8.6M | $14.7M | -$20.5M | -$24.9M | -$29.4M | -$28.0M | -$35.1M | -$43.5M | -$45.6M | -$45.2M |
| Operating cash flow | -$6.4M | -$9.5M | $2.1M | -$7.1M | -$12.4M | -$28.5M | -$12.5M | -$27.1M | -$17.3M | -$38.4M | -$26.9M | -$46.7M |
| Free cash flow | -$7.6M | -$10.3M | $1.4M | -$7.5M | -$13.1M | -$29.7M | -$12.6M | -$27.4M | -$19.0M | -$39.9M | -$28.2M | -$49.5M |
| Diluted shares | 159.9M | 155.5M | 142.4M | 163.2M | 152.1M | 149.2M | 147.7M | 147.5M | 147.4M | 145.8M | 144.9M | 144.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $169.9M | $77.6M | $70.5M | $55.0M | $43.2M | $50.6M |
| Short-term investments | $174.4M | $140.8M | $156.5M | $157.7M | $154.7M | $142.8M |
| Total debt | $334.9M | $130.6M | $131.2M | $131.8M | $133.6M | $133.6M |
| Total assets | $640.7M | $505.9M | $512.7M | $490.6M | $496.6M | $510.9M |
| Total liabilities | $490.0M | $281.7M | $287.7M | $286.4M | $317.1M | $320.6M |
| Shareholders' equity | $150.7M | $224.2M | $225.0M | $204.3M | $179.5M | $190.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology